
What Is It?
Sanofi is committed to collaborating with partners to advance cutting-edge discoveries. The Sanofi Innovations in Data Exploration and Analytics (iDEA) Awards program, launched in 2018, provides seed funding to innovators at research centers and early start-ups across North America to transform breakthrough digital, data science tools and new technologies into solutions that accelerate the R&D pipeline and improve people’s lives. In 2022, the iDEA awards (NA) and iTECH awards (Europe) merged into the Sanofi global iDEA-TECH awards.
About the Program
- Seed funding of $150.000 USD
- 1 year project duration
- Dedicated Sanofi Project Champion and resources (subject matter experts)
- A stepping stone to further collaboration
The Next Project Call is Anticipated for November 2026
Examples of Partnering Opportunities
Predict patient outcomes
Predict & track disease progression & drug effects
Maximize drug value in the real world
Optimize clinical trial design
Drug target enabling platforms
Biomarker Identification
Test new digital/AI solutions
High throughput screening approaches
Analytic tools to understand drug mechanism or product quality
Testimonials

“The iDEA-TECH Awards initiative is providing a unique opportunity to work as a team to study itch in kids with atopic dermatitis in the comfort of their homes by incorporating our Emerald AI technology. It has been exciting to work so closely with the Sanofi team around a shared commitment to breaking new grounds for this important population.”
Dina Katabi, PhD, Thuan and Nicole Pham Professor, MIT President and co-Founder, Emerald Innovations, Inc.
Sanofi iDEA-TECH Awards
Recent award recipients share how winning this award and collaborating with Sanofi researchers has impacted their work.
iDEA-TECH Recipients for 2025-2026
Isaac Lutz
Aptamino
Jeffrey Petrella
Duke University Health
Marinka Zitnik
Harvard University, Harvard Medical School
Jinfeng Zhang
Insilicom LLC
Joel Bader
Johns Hopkins University
Anjalie Field
Johns Hopkins University
Hai-Quan Mao
Johns Hopkins University
Morgan Chandler
MIMETAS Operations Us, Co
Anna Jezierski
National Research Council of Canada
Scott Tenenbaum
sxRNA Technologies, Inc.
Narendra Tallapragada
Tessel Biosciences
Wenpeng Yin and Wenrui Hao
The Pennsylvania State University
Le Bao
The Pennsylvania State University
Omar Din
University of California, San Diego
Jingchuan Guo
Regenstrief Institute
Kevin Weeks
University of North Carolina at Chapel Hill
Matthew Champion
University of Notre Dame
Vadim Cherezov
University of Southern California
Joint Publications
Uncovering New Therapeutic Targets for Amyotrophic Lateral Sclerosis (ALS) and Neurological Diseases Using Real-World Data
UCLA, Jennifer Wilson, 2025
Evaluating the robustness of an AI pathfinder application on eligibility criteria in multiple myeloma trials using real-world data and historical trials
Weill Cornell Medical College, Fei Wang, 2024
Characterizing the connection between Parkinson’s disease progression and healthcare utilization
Harvard, Brett Beaulieu-Jones, 2024
Learning the Language of Antibody Hypervariability
MIT, Berger, 2024
Disease Progression Strikingly Differs in Research and Real-World Parkinson’s Populations
Harvard Medical School, Brett Beaulieu-Jones and Isaac Kohane, 2024



